Clinical long-acting medication for osteoporosis patients is mainly zoledronic acid injection, which is usually given once a year instead of once every six months. Osteoporosis patients are usually elderly or postmenopausal women mostly, due to metabolic slowdown, endocrine disorders and other factors, resulting in the body’s osteoblasts and osteoclasts bone metabolism to lose the dynamic balance, the loss of bone is serious. Before injecting zoledronic acid injection, it is required to improve the bone metabolism, bone density and other related examinations, and clearly diagnosed as severe osteoporosis, i.e., T less than 3.0 with fragility fracture, if there is no special contraindication, it can be recommended to inject zoledronic acid injection. Zoledronic acid injection may produce adverse reactions such as dizziness and vomiting, and the treatment must be completed under the supervision of a physician and in accordance with the doctor’s instructions.